Drugs / extrahepatic cholangiocyte organoids
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07214649 | Jan 2026 → Jun 2030 expected | hepatobiliary disorder | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | extrahepatic cholangiocyte organoids | “Recent advances in regenerative medicine, particularly the development of extrahepatic cholangiocyte organoids (ECOs), offer a promising alternative.” NCT07214649 ↗ |
| Known as | ECOs | “Recent advances in regenerative medicine, particularly the development of extrahepatic cholangiocyte organoids (ECOs), offer a promising alternative.” NCT07214649 ↗ |
| Modality | Cell therapy | “autologous ECO-based cell therapy to reconstruct bile ducts” NCT07214649 ↗ |
| Route | Other | “delivered to the site of injury through radiological or endoscopic routes” NCT07214649 ↗ |